WO2017011418A1 - ORGANIC REACTION UTILIZING AN α,β-UNSATURATED COMPOUND - Google Patents

ORGANIC REACTION UTILIZING AN α,β-UNSATURATED COMPOUND Download PDF

Info

Publication number
WO2017011418A1
WO2017011418A1 PCT/US2016/041816 US2016041816W WO2017011418A1 WO 2017011418 A1 WO2017011418 A1 WO 2017011418A1 US 2016041816 W US2016041816 W US 2016041816W WO 2017011418 A1 WO2017011418 A1 WO 2017011418A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
aziridine
alkyl
group
Prior art date
Application number
PCT/US2016/041816
Other languages
French (fr)
Inventor
Jon Njardarson
Isaac CHOGII
Original Assignee
Arizona Board Of Regents On Behalf Of The University Of Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizona Board Of Regents On Behalf Of The University Of Arizona filed Critical Arizona Board Of Regents On Behalf Of The University Of Arizona
Publication of WO2017011418A1 publication Critical patent/WO2017011418A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to a method for producing various aziridine or dihydrofuran compounds that can be used in synthesizing various natural products and pharmaceutically active compounds.
  • the present invention relates to using an ⁇ , ⁇ - unsaturated compound to produce various aziridine compounds and dihydrofuran compounds.
  • the present invention relates to a method for producing an aziridine compounds of the formula:
  • Aziridine and dihydrofuran compounds are important intermediates in synthesis of natural products and pharmaceutically active compounds. While some methods are available for producing various aziridine and dihydrofuran compounds, they often require a circuitous synthetic route, require expensive reagents, require heavy metals that are toxic to mammals, require extensive protection/deprotection steps, do not provide chiral synthesis or provide a low enantiomeric selectivity, or result in only a moderate to low yield of aziridine compounds. [0004] In addition, conventional methods for producing dihydrofuran compounds also suffer from some of the limitation discussed above, including but not limited to, requiring a circuitous synthetic route, use of expensive reagents and/or heavy metals that are toxic to mammals. Furthermore, as with aziridine synthesis, conventional methods for producing dihydrofuran also often requires extensive protecti on/deprotecti on steps and often provide only a moderate to low overall yield of dihydrofuran compounds.
  • One aspect of the invention provides a method for producing various aziridine compounds including, but not limited to, enantiomerically and/or diastereomerically enriched aziridine compounds.
  • chiral aziridine compounds are produced in a single step.
  • the method of the invention provides easy access to various aziridine compounds including, but not limited to, chiral (i.e., enantiomerically and/or diastereomerically enriched) aziridine compounds.
  • Another aspect of the invention provides a method for producing various dihydrofuran compounds.
  • the invention provides a method or a process for producing 2, 5 -dihydrofuran compounds.
  • the method provides a synthesis of 2, 3 -di substituted 2, 5 -dihydrofuran compounds.
  • the method or process produces dihydrofuran compounds in a single step.
  • the method of the invention utilizes an ⁇ , ⁇ -unsaturated compound of the formula: where R 1 is hydrogen, alkyl, haloalkyl, aryl, aralkyl, alkenyl, aralkenyl, cycloalkyl, heteroalkyl, or heteroaryl; or R 1 together with W form a heterocycloalkyl; X is a leaving group; andW is an electron withdrawing group.
  • Alkyl refers to a saturated linear monovalent hydrocarbon moiety of one to twelve, typically one to six, carbon atoms or a saturated branched monovalent hydrocarbon moiety of three to twelve, preferably three to six, carbon atoms.
  • Exemplary alkyl group include, but are not limited to, methyl, ethyl, ⁇ -propyl, 2-propyl, tert-butyl, pentyl, and the like.
  • Alkylene refers to a saturated linear divalent hydrocarbon moiety of one to twelve, typically one to six, carbon atoms or a branched saturated divalent hydrocarbon moiety of three to twelve, preferably three to six, carbon atoms.
  • exemplary alkylene groups include, but are not limited to, methylene, ethylene, propylene, butylene, pentylene, and the like.
  • Aryl refers to a monovalent mono-, bi- or tricyclic aromatic hydrocarbon moiety of 6 to 15 ring atoms which is optionally substituted with one or more, preferably one, two, or three substituents within the ring structure. When two or more substituents are present in an aryl group, each substituent is independently selected. Exemplary substituents for the aryl group include, but are not limited to, alkyl, haloalkyl, thioalkyl, heteroalkyl, halo, nitro, cyano, cycloalkyl, aryl, heteroaryl, heterocyclyl, haloalkoxy, aryloxy, heteroaryloxy, etc.
  • Aralkyl refers to a moiety of the formula -R b R c where R b is an alkylene group and R c is an aryl group as defined herein.
  • exemplary aralkyl groups include, but are not limited to, benzyl, phenylethyl, 3-(3-chlorophenyl)-2-methylpentyl, and the like.
  • Chiral center i.e., stereochemical center, stereocenter, or stereogenic center refers to an asymmetrically substituted atom, e.g., a carbon atom to which four different groups are attached.
  • the ultimate criterion of a chiral center is nonsuperimposability of its mirror image.
  • Cycloalkyl refers to a non-aromatic, preferably saturated, monovalent mono- or bicyclic hydrocarbon moiety of three to ten ring carbons.
  • the cycloalkyl can be optionally substituted with one or more, preferably one, two, or three, substituents within the ring structure. When two or more substituents are present in a cycloalkyl group, each substituent is
  • Cycloalkylalkyl refers to a moiety of the formula -R d R e where R d is an alkylene group and R e is a cycloalkyl group as defined herein.
  • Exemplary cycloalkylalkyl groups include, but are not limited to, cyclopropylmethyl, cyclohexylpropyl, 3-cyclohexyl-2-methylpropyl, and the like.
  • heteroalkylalkyl refers to -R f R s where R f is an alkylene group and R s is a heteroalkyl, heteroaryl, and aryl, respectively, as defined herein
  • halo halogen
  • halide halogen
  • Haloalkyl refers to an alkyl group as defined herein in which one or more hydrogen atom is replaced by same or different halo atoms.
  • haloalkyl also includes perhalogenated alkyl groups in which all alkyl hydrogen atoms are replaced by halogen atoms.
  • Exemplary haloalkyl groups include, but are not limited to, -CH 2 C1, -CF 3 , -CH 2 CF 3 , -CH 2 CC1 , and the like.
  • Heteroalkyl refers to a branched or unbranched, cyclic or preferably acyclic saturated alkyl moiety containing carbon, hydrogen and one or more heteroatoms in place of a carbon atom, or optionally one or more heteroatom-containing substituents independently selected from -OR a , -C(0)R a , - R b R c , -C(0)NR b R c and -S(0) predominantlyR d (where n is an integer from 0 to 2 ).
  • R a is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl,
  • R b is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl,
  • R c is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, acyl, alkylsulfonyl, carboxamido, or mono- or di- alkylcarbomoyl.
  • R b and R c can be combined together with the nitrogen to which each is attached to form a four-, five-, six- or seven-membered heterocyclic ring (e.g., a pyrrolidinyl, piperidinyl or morpholinyl ring).
  • R d is hydrogen (provided that n is 0), alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, acyl, amino, monsubstituted amino, disubstituted amino, or hydroxy alkyl.
  • Heterocyclyl means a non-aromatic monocyclic moiety of three to eight ring atoms in which one or two ring atoms are heteroatoms selected from N, O, or S(0) n (where n is an integer from 0 to 2), the remaining ring atoms being C, where one or two C atoms can optionally be a carbonyl group.
  • the heterocyclyl ring can be optionally substituted
  • heterocyclyl group independently with one or more, preferably one, two, or three, substituents.
  • substituents for heterocyclyl group include, but are not limited to, alkyl, haloalkyl, heteroalkyl, halo, nitro, cyano, aryl, heteroaryl, aralkyl, heteroaralkyl, etc.
  • the percentage of enantiomeric excess can be calculated by subtracting the percentage of one enantiomer from the percentage of the other enantiomer. For example, if the %ee of (R)-enantiomer is 99% and %ee of (S)-enantiomer is 1%, the %ee of (R)- isomer is 99%-l% or 98%.
  • Diastereomeric excess refers to the difference between the amount of diastereomers.
  • the percentage of diastereomeric excess (% d.e, or %de) can be calculated by subtracting the percentage of one diastereomer from the percentage of the other diastereomers. For example, if the %de of (R,R)-diastereomer is 99% and %de of all other diastereomers (e.g., (R,S)-, (S,S)- and (S,R)-diastereomers) is 1%, the %de of (R,R)-isomer is 99%-l% or 98%.
  • leaving group has the meaning conventionally associated with it in synthetic organic chemistry, i.e., an atom or a group capable of being displaced by a nucleophile and includes halo (such as chloro, bromo, and iodo), alkanesulfonyloxy, arenesulfonyloxy, alkylcarbonyloxy (e.g., acetoxy), arylcarbonyloxy, mesyloxy, tosyloxy,
  • trifluoromethanesulfonyloxy aryloxy (e.g., 2,4-dinitrophenoxy), methoxy, ⁇ , ⁇ - dimethylhydroxylamino, and the like.
  • leaving groups include, but are not limited to, CI, Br, I and sulfonate esters such as OMs (mesylate), OTs (tosylate), ONs (nosylate), OTf (triflate) and any other sulfonate esters.
  • electron withdrawing group refers an atom or a functional group that removes electron density from a conjugated ⁇ system via resonance or inductive electron withdrawal, thus making the ⁇ system more electrophilic.
  • ⁇ , ⁇ -unsaturated compound refers to any compound that has ⁇ , ⁇ - unsaturation near the electron withdrawing group.
  • the ⁇ , ⁇ - unsaturated compounds of the invention can also have other unsaturated bond(s) that is conjugated to the ⁇ , ⁇ -unsaturation.
  • the term ⁇ , ⁇ -unsaturated compound includes other extended conjugated compounds, such as ⁇ , ⁇ - and ,d- unsaturated compounds as well as other more extended conjugated compounds.
  • Protecting group refers to a moiety, except alkyl groups, that when attached to a reactive group in a molecule masks, reduces or prevents that reactivity. Examples of protecting groups can be found in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3 edition, John Wiley & Sons, New York, 1999, and Harrison and Harrison et al., Compendium of Synthetic Organic Methods, Vols. 1-8 (John Wiley and Sons, 1971-1996), which are incorporated herein by reference in their entirety.
  • Representative hydroxy protecting groups include acyl groups, benzyl and trityl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers and allyl ethers.
  • Representative amino protecting groups include, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (CBZ), tert-butoxycarbonyl (Boc), trimethyl silyl (TMS), 2- trimethylsilyl-ethanesulfonyl (SES), trityl and substituted trityl groups, allyloxycarbonyl, 9- fluorenylmethyloxycarbonyl (FMOC), nitro-veratryloxycarbonyl (NVOC), and the like.
  • Corresponding protecting group means an appropriate protecting group corresponding to the heteroatom (i.e., N, O, P or S) to which it is attached.
  • reacting are used interchangeably herein, and refer to adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product.
  • One particular aspect of the invention provides methods and processes for producing aziridine compounds.
  • One particular aspect of the invention provides a method for producing an aziridine compound of the formula:
  • said method comprising:
  • each of a and b is a chiral center
  • R is alkyl, haloalkyl, aryl, aralkyl, alkenyl, aralkenyl, cycloalkyl, heteroalkyl, or
  • R 1 is hydrogen, alkyl, haloalkyl, aryl, aralkyl, alkenyl, aralkenyl, cycloalkyl, heteroalkyl, or heteroaryl; or R 1 together with W form a heterocycloalkyl X is a leaving group;
  • W is an electron withdrawing group
  • Y is an auxiliary group.
  • compound of Formula A-II can also include one or more substituents (e.g., alkyl, halo, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl heterocycloalkyl, haloalkyl, etc.) on the a-position of the carbonyl group.
  • substituents e.g., alkyl, halo, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl heterocycloalkyl, haloalkyl, etc.
  • R 1 is hydrogen or alkyl or together with W form a heterocyclyl.
  • the electron withdrawing group comprises -S0 2 R,
  • each R is independently alkyl, typically Ci-Ci 2 alkyl, and often Ci-C 6 alkyl.
  • Y is a chiral auxiliary group.
  • the chiral auxiliary group is a moiety of the formula: where
  • R a is alkyl, cycloalkyl, aralkyl, alkenyl, aralkenyl, heteroalkyl, or heteroaryl.
  • the enantiomeric excess of starting material has a great influence on the diastereomeric and/or enantiomeric excess of the product (i.e., aziridine compound of Formula A-I).
  • imine compound of Formula A-III that is used in the method of invention has enantiomeric excess of at least 99 % e.e.
  • the aziridine compound that is produced using the method of the invention is diastereomerically enriched. It should be appreciated that diastereomeric excess and
  • enantiomeric excess described herein refer to diastereomeric excess and enantiomeric excess, respectively, prior to any separation step or stereoisomer enrichment step. [0036] In one particular embodiment, the diastereomeric excess of aziridine compound of
  • Formula A is at least 95% d.e.
  • R and R a are those defined herein.
  • R a is tert-butyl.
  • the method of the invention provides an aziridine substituted furanone of the formula:
  • a typical reaction involves deprotonating an ⁇ , ⁇ -unsaturated furanone compound of the formula:
  • each of a and b is a chiral center
  • R is alkyl, haloalkyl, aryl, aralkyl, alkenyl, aralkenyl, cycloalkyl, heteroalkyl, or
  • X is a leaving group
  • Y is an auxiliary group.
  • compound of Formula Al-II can also include one or more substituents (e.g., alkyl, halo, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl heterocycloalkyl, haloalkyl, etc.) on the a-position of the carbonyl group.
  • substituents e.g., alkyl, halo, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl heterocycloalkyl, haloalkyl, etc.
  • Y is a chiral auxiliary group.
  • chiral auxiliary group is a moiety of the formula: where
  • the squiggly line indicates the point of attachment of the chiral auxiliary group to the nitrogen atom
  • R a is alkyl, cycloalkyl, aralkyl, alkenyl, aralkenyl, heteroalkyl, or heteroaryl.
  • the imine compound A-III has enantiomeric excess of at least 90 %ee, typically at least 95 %ee, and often at least 99 %e.e. Accordingly, in some instances, the aziridine substituted furanone compound that is produced by the method of the invention is diastereomerically enriched. In some embodiments, the method of invention produces the aziridine substituted furanone compound of Formula Al-I in a diastereomeric excess of at least 90% de, typically at least 95% de, and often at least 98% de.
  • the method of invention includes a step of removing the chiral auxiliary group. Removal of the chiral auxiliary group Y provides an aziridine substituted furanone compound in which only the chiral centers "a" and "b" are present.
  • the method provides an aziridine substituted compound whose enantiomerically enrichment is at least about 90%, typically at least about 95%), and often at least about 98%>.
  • Another aspect of the invention provides a method for producing a dihydrofuran compound.
  • the reaction involves deprotonating an ⁇ , ⁇ -unsaturated compound of the formula:
  • W is an electron withdrawing group
  • X is a leaving group
  • R is alkyl, haloalkyl, heteroalkyl, aryl, aralkyl, alkenyl, aralkenyl, cycloalkyl, heteroalkyl, or heteroaryl.
  • the compound B-2 can also include one or more substituents (e.g., alkyl, halo, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl heterocycloalkyl, haloalkyl, etc.) on the ⁇ , ⁇ and/or ⁇ -position of the electron withdrawing group, W.
  • substituents e.g., alkyl, halo, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl heterocycloalkyl, haloalkyl, etc.
  • the method of the invention provides a dihydrofuran compound in a yield of at least about 50%, typically at least about 60%, and often at least about 75%.
  • Example 1 General Procedure for the Synthesis of aziridine substituted fur anone compounds: To a flask equipped with magnetic stir bar and diisopropyl amine (2.0 eq. in THF, - 78 °C) was added «-butyl lithium (2.0 eq.) after which the solution was warmed to 0 °C and allowed to stir for 15 minutes. The resulting lithium diisopropyl amide (LDA) solution was then cooled to -78 °C and additional THF was added to reach an overall concentration of 0.1 M based on the sulfinimine. To the LDA solution, O.
  • LDA lithium diisopropyl amide
  • Example 2 Using the corresponding enantiomer of the imine compound, a similar yield of the an enantiomer of compounds produced in Example 1 were also obtained as illustrated below.
  • Example 3 General Procedure for the Synthesis of dihydrofuran compounds: To a flask equipped with magnetic stir bar and diisopropyl amine (3.0 eq. in THF, -78 °C) was added «-butyl lithium (2.0 eq.) after which the solution was warmed to 0 °C and allowed to stir for 15 minutes. The resulting lithium diisopropyl amide (LDA) solution was then cooled to -78 °C and additional THF was added to reach an overall concentration of 0.1 M based on the sulfinimine.
  • LDA lithium diisopropyl amide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a various organic reaction that utilize an α,β-unsaturated compound to produce aziridine compounds and dihydrofuran compounds. In particular, the present invention provides a method for producing an aziridine compounds of the formula : (I) or a dihydrofuran compound of the formula: (II) by reacting an α,β-unsaturated compound of the formula: (III) with an appropriate compound. In this manner a wide variety of aziridine compounds and dihydrofuran compounds can be produced using the method of the invention.

Description

ORGANIC REACTION UTILIZING AN α, β -UNSATURATED
COMPOUND
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the priority benefit of U.S. Provisional Application Nos.
62/190,924 and 62/190,928, both of which were filed on July 10, 2015, and both of which are incorporated herein by reference in their entirety.
FIELD OF THE INVENTION
[0002] The present invention relates to a method for producing various aziridine or dihydrofuran compounds that can be used in synthesizing various natural products and pharmaceutically active compounds. In particular, the present invention relates to using an α,β- unsaturated compound to produce various aziridine compounds and dihydrofuran compounds. In particular, the present invention relates to a method for producing an aziridine compounds of the formula:
Figure imgf000003_0001
or a dihydrofuran compound of the formula: 0 by reacting an α,β-
R
unsaturated compound of the formula: with an appropriate starting material. In this manner a wide variety of aziridine compounds and dihydrofuran compounds can be produced using the method of the invention.
BACKGROUND OF THE INVENTION
[0003] Aziridine and dihydrofuran compounds are important intermediates in synthesis of natural products and pharmaceutically active compounds. While some methods are available for producing various aziridine and dihydrofuran compounds, they often require a circuitous synthetic route, require expensive reagents, require heavy metals that are toxic to mammals, require extensive protection/deprotection steps, do not provide chiral synthesis or provide a low enantiomeric selectivity, or result in only a moderate to low yield of aziridine compounds. [0004] In addition, conventional methods for producing dihydrofuran compounds also suffer from some of the limitation discussed above, including but not limited to, requiring a circuitous synthetic route, use of expensive reagents and/or heavy metals that are toxic to mammals. Furthermore, as with aziridine synthesis, conventional methods for producing dihydrofuran also often requires extensive protecti on/deprotecti on steps and often provide only a moderate to low overall yield of dihydrofuran compounds.
[0005] Therefore, there is a continuing need for a relatively efficient and inexpensive method for producing important aziridine and dihydrofuran compounds that can be used in synthesis of natural products and pharmaceutically active compounds.
SUMMARY OF THE INVENTION
[0006] One aspect of the invention provides a method for producing various aziridine compounds including, but not limited to, enantiomerically and/or diastereomerically enriched aziridine compounds. In some particular embodiments of the invention, chiral aziridine compounds are produced in a single step. The method of the invention provides easy access to various aziridine compounds including, but not limited to, chiral (i.e., enantiomerically and/or diastereomerically enriched) aziridine compounds.
[0007] Another aspect of the invention provides a method for producing various dihydrofuran compounds. In one particular embodiment, the invention provides a method or a process for producing 2, 5 -dihydrofuran compounds. Still in another embodiment of the invention, the method provides a synthesis of 2, 3 -di substituted 2, 5 -dihydrofuran compounds. In some embodiments of the invention, the method or process produces dihydrofuran compounds in a single step.
[0008] In general, the method of the invention utilizes an α,β-unsaturated compound of the formula:
Figure imgf000004_0001
where R1 is hydrogen, alkyl, haloalkyl, aryl, aralkyl, alkenyl, aralkenyl, cycloalkyl, heteroalkyl, or heteroaryl; or R1 together with W form a heterocycloalkyl; X is a leaving group; andW is an electron withdrawing group. DETAILED DESCRIPTION OF THE INVENTION
[0009] Definitions:
[0010] "Alkyl" refers to a saturated linear monovalent hydrocarbon moiety of one to twelve, typically one to six, carbon atoms or a saturated branched monovalent hydrocarbon moiety of three to twelve, preferably three to six, carbon atoms. Exemplary alkyl group include, but are not limited to, methyl, ethyl, ^-propyl, 2-propyl, tert-butyl, pentyl, and the like.
[0011] "Alkylene" refers to a saturated linear divalent hydrocarbon moiety of one to twelve, typically one to six, carbon atoms or a branched saturated divalent hydrocarbon moiety of three to twelve, preferably three to six, carbon atoms. Exemplary alkylene groups include, but are not limited to, methylene, ethylene, propylene, butylene, pentylene, and the like.
[0012] "Aryl" refers to a monovalent mono-, bi- or tricyclic aromatic hydrocarbon moiety of 6 to 15 ring atoms which is optionally substituted with one or more, preferably one, two, or three substituents within the ring structure. When two or more substituents are present in an aryl group, each substituent is independently selected. Exemplary substituents for the aryl group include, but are not limited to, alkyl, haloalkyl, thioalkyl, heteroalkyl, halo, nitro, cyano, cycloalkyl, aryl, heteroaryl, heterocyclyl, haloalkoxy, aryloxy, heteroaryloxy, etc.
[0013] "Aralkyl" refers to a moiety of the formula -RbRc where Rb is an alkylene group and Rc is an aryl group as defined herein. Exemplary aralkyl groups include, but are not limited to, benzyl, phenylethyl, 3-(3-chlorophenyl)-2-methylpentyl, and the like.
[0014] "Chiral center" (i.e., stereochemical center, stereocenter, or stereogenic center) refers to an asymmetrically substituted atom, e.g., a carbon atom to which four different groups are attached. The ultimate criterion of a chiral center, however, is nonsuperimposability of its mirror image.
[0015] "Cycloalkyl" refers to a non-aromatic, preferably saturated, monovalent mono- or bicyclic hydrocarbon moiety of three to ten ring carbons. The cycloalkyl can be optionally substituted with one or more, preferably one, two, or three, substituents within the ring structure. When two or more substituents are present in a cycloalkyl group, each substituent is
independently selected. Exemplary substituents for cycloalkyl group include, but are not limited to, alkyl, haloalkyl, halo, nitro, cyano, heteroalkyl, aryl, heteroaralkyl, etc. [0016] "Cycloalkylalkyl" refers to a moiety of the formula -RdRe where Rd is an alkylene group and Re is a cycloalkyl group as defined herein. Exemplary cycloalkylalkyl groups include, but are not limited to, cyclopropylmethyl, cyclohexylpropyl, 3-cyclohexyl-2-methylpropyl, and the like. Similarly, terms heteroalkylalkyl, heteroaralkyl (or heteroaralkyl), aralkyl (or arylalkyl) refers to -RfRs where Rf is an alkylene group and Rs is a heteroalkyl, heteroaryl, and aryl, respectively, as defined herein
[0017] The terms "halo," "halogen" and "halide" are used interchangeably herein and refer to fluoro, chloro, bromo, or iodo.
[0018] "Haloalkyl" refers to an alkyl group as defined herein in which one or more hydrogen atom is replaced by same or different halo atoms. The term "haloalkyl" also includes perhalogenated alkyl groups in which all alkyl hydrogen atoms are replaced by halogen atoms. Exemplary haloalkyl groups include, but are not limited to, -CH2C1, -CF3, -CH2CF3, -CH2CC1 , and the like.
[0019] "Heteroalkyl" refers to a branched or unbranched, cyclic or preferably acyclic saturated alkyl moiety containing carbon, hydrogen and one or more heteroatoms in place of a carbon atom, or optionally one or more heteroatom-containing substituents independently selected from -ORa, -C(0)Ra, - RbRc, -C(0)NRbRc and -S(0)„Rd (where n is an integer from 0 to 2 ). Ra is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl,
heterocyclylalkyl, aryl, aralkyl, heteroaryl or heteroaralkyl. Rb is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl,
heteroaralkyl, or acyl. Rc is hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, acyl, alkylsulfonyl, carboxamido, or mono- or di- alkylcarbomoyl. Optionally, Rb and Rc can be combined together with the nitrogen to which each is attached to form a four-, five-, six- or seven-membered heterocyclic ring (e.g., a pyrrolidinyl, piperidinyl or morpholinyl ring). Rd is hydrogen (provided that n is 0), alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, heterocyclylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, acyl, amino, monsubstituted amino, disubstituted amino, or hydroxy alkyl.
Representative examples include, for example, 2-methoxyethyl, benzyloxymethyl, thiophen-2- ylthiomethyl, 2-hydroxyethyl, and 2,3-dihydroxypropyl. [0020] "Heterocyclyl" means a non-aromatic monocyclic moiety of three to eight ring atoms in which one or two ring atoms are heteroatoms selected from N, O, or S(0)n (where n is an integer from 0 to 2), the remaining ring atoms being C, where one or two C atoms can optionally be a carbonyl group. The heterocyclyl ring can be optionally substituted
independently with one or more, preferably one, two, or three, substituents. When two or more substituents are present in a heterocyclyl group, each substituent is independently selected. Exemplary substituents for heterocyclyl group include, but are not limited to, alkyl, haloalkyl, heteroalkyl, halo, nitro, cyano, aryl, heteroaryl, aralkyl, heteroaralkyl, etc.
[0021] "Enantiomeric excess" refers to the difference between the amount of
enantiomers. The percentage of enantiomeric excess (% e.e, or %ee) can be calculated by subtracting the percentage of one enantiomer from the percentage of the other enantiomer. For example, if the %ee of (R)-enantiomer is 99% and %ee of (S)-enantiomer is 1%, the %ee of (R)- isomer is 99%-l% or 98%.
[0022] "Diastereomeric excess" refers to the difference between the amount of diastereomers. The percentage of diastereomeric excess (% d.e, or %de) can be calculated by subtracting the percentage of one diastereomer from the percentage of the other diastereomers. For example, if the %de of (R,R)-diastereomer is 99% and %de of all other diastereomers (e.g., (R,S)-, (S,S)- and (S,R)-diastereomers) is 1%, the %de of (R,R)-isomer is 99%-l% or 98%.
[0023] "Leaving group" has the meaning conventionally associated with it in synthetic organic chemistry, i.e., an atom or a group capable of being displaced by a nucleophile and includes halo (such as chloro, bromo, and iodo), alkanesulfonyloxy, arenesulfonyloxy, alkylcarbonyloxy (e.g., acetoxy), arylcarbonyloxy, mesyloxy, tosyloxy,
trifluoromethanesulfonyloxy, aryloxy (e.g., 2,4-dinitrophenoxy), methoxy, Ν,Ο- dimethylhydroxylamino, and the like. Specific examples of leaving groups include, but are not limited to, CI, Br, I and sulfonate esters such as OMs (mesylate), OTs (tosylate), ONs (nosylate), OTf (triflate) and any other sulfonate esters.
[0024] The term "electron withdrawing group" refers an atom or a functional group that removes electron density from a conjugated π system via resonance or inductive electron withdrawal, thus making the π system more electrophilic. Exemplary electron withdrawing groups that are useful in the invention include, but are not limited to, esters, sulfonyl (e.g., a moiety of the formula: -S02Ra, where Ra is alkyl), alkylsulfates (e.g., a moiety of the formula: - OS(0)2ORa, where Ra is alkyl), aldehydes, nitro groups (-NOn, where n is 1 or 2), nitriles, phosphonates (e.g., -OP0 Ra or -P(=0)(ORa)2, where each Ra is independently alkyl), amides (- CONRaRb, where each of Ra and Rb is independently alkyl, cycloalkyl, cycloalkylalkyl, or Ra and Rb together with the nitrogen atom to which they are attached form a nitrogen containing heterocyclyl), ketones, as well as other heteroatom containing functional groups.
[0025] The term "α,β-unsaturated compound" refers to any compound that has α,β- unsaturation near the electron withdrawing group. Such a compound can be generally represented as Ra-CRb=CRc-Z, where Z is an electron withdrawing group as defined herein and each of Ra, Rb and Rc is independently hydrogen or carbon atom containing group. The α,β- unsaturated compounds of the invention can also have other unsaturated bond(s) that is conjugated to the α,β-unsaturation. Thus, the term α,β-unsaturated compound includes other extended conjugated compounds, such as α,β- and ,d- unsaturated compounds as well as other more extended conjugated compounds.
[0026] "Protecting group" refers to a moiety, except alkyl groups, that when attached to a reactive group in a molecule masks, reduces or prevents that reactivity. Examples of protecting groups can be found in T.W. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 3 edition, John Wiley & Sons, New York, 1999, and Harrison and Harrison et al., Compendium of Synthetic Organic Methods, Vols. 1-8 (John Wiley and Sons, 1971-1996), which are incorporated herein by reference in their entirety. Representative hydroxy protecting groups include acyl groups, benzyl and trityl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers and allyl ethers. Representative amino protecting groups include, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl (CBZ), tert-butoxycarbonyl (Boc), trimethyl silyl (TMS), 2- trimethylsilyl-ethanesulfonyl (SES), trityl and substituted trityl groups, allyloxycarbonyl, 9- fluorenylmethyloxycarbonyl (FMOC), nitro-veratryloxycarbonyl (NVOC), and the like.
[0027] "Corresponding protecting group" means an appropriate protecting group corresponding to the heteroatom (i.e., N, O, P or S) to which it is attached.
[0028] When describing a chemical reaction, the terms "treating", "contacting" and
"reacting" are used interchangeably herein, and refer to adding or mixing two or more reagents under appropriate conditions to produce the indicated and/or the desired product. It should be appreciated that the reaction which produces the indicated and/or the desired product may not necessarily result directly from the combination of two reagents which were initially added, i.e., there may be one or more intermediates which are produced in the mixture which ultimately leads to the formation of the indicated and/or the desired product.
[0029] As used herein, the terms "those defined above" and "those defined herein" when referring to a variable incorporates by reference the broad definition of the variable as well as any narrow and/or preferred, more preferred and most preferred definitions, if any.
[0030] Method for producing Aziridine Compounds : One particular aspect of the invention provides methods and processes for producing aziridine compounds. One particular aspect of the invention provides a method for producing an aziridine compound of the formula:
Figure imgf000009_0001
A-I
said method comprising:
deprotonating an α,β-unsaturated com ound of the formula:
Figure imgf000009_0002
with a base under condition sufficient to produce a deprotonated intermediate; and reacting said deprotonated intermediate an imine compound of the formula:
A-III
under conditions sufficient to produce said aziridine compound of Formula A-I, wherein
each of a and b is a chiral center;
R is alkyl, haloalkyl, aryl, aralkyl, alkenyl, aralkenyl, cycloalkyl, heteroalkyl, or
heteroaryl;
R1 is hydrogen, alkyl, haloalkyl, aryl, aralkyl, alkenyl, aralkenyl, cycloalkyl, heteroalkyl, or heteroaryl; or R1 together with W form a heterocycloalkyl X is a leaving group;
W is an electron withdrawing group; and
Y is an auxiliary group.
[0031] It should be appreciated that compound of Formula A-II can also include one or more substituents (e.g., alkyl, halo, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl heterocycloalkyl, haloalkyl, etc.) on the a-position of the carbonyl group.
[0032] In some embodiments, R1 is hydrogen or alkyl or together with W form a heterocyclyl.
[0033] In another embodiment, the electron withdrawing group comprises -S02R,
-COR, -N02, -P=0(OR)2 or -C02R, where each R is independently alkyl, typically Ci-Ci2 alkyl, and often Ci-C6 alkyl.
[0034] Yet in other embodiments, Y is a chiral auxiliary group. By using the chiral auxiliary group, methods of the invention provide a diastereomerically and/or enantiomerically enriched aziridine compound. In one particular embodiment, the chiral auxiliary group is a moiety of the formula:
Figure imgf000010_0001
where
* denotes a chiral center; and
Ra is alkyl, cycloalkyl, aralkyl, alkenyl, aralkenyl, heteroalkyl, or heteroaryl.
[0035] As would be expected, the enantiomeric excess of starting material has a great influence on the diastereomeric and/or enantiomeric excess of the product (i.e., aziridine compound of Formula A-I). Accordingly, in one particular embodiment, imine compound of Formula A-III that is used in the method of invention has enantiomeric excess of at least 99 % e.e. In this manner, the aziridine compound that is produced using the method of the invention is diastereomerically enriched. It should be appreciated that diastereomeric excess and
enantiomeric excess described herein refer to diastereomeric excess and enantiomeric excess, respectively, prior to any separation step or stereoisomer enrichment step. [0036] In one particular embodiment, the diastereomeric excess of aziridine compound of
Formula A is at least 95% d.e.
[0037] One specific example of the imine compound that is used in the method of invention has the following formula:
O II
'
Figure imgf000011_0001
where R and Ra are those defined herein. Within this example, in one instance, Ra is tert-butyl.
[0038] In one particular aspect of the invention, the method of the invention provides an aziridine substituted furanone of the formula:
Figure imgf000011_0002
Al-I
In this aspect of the invention, a typical reaction involves deprotonating an α,β-unsaturated furanone compound of the formula:
Figure imgf000011_0003
Al-II
with a base under condition sufficient to produce a deprotonated intermediate; and reacting said deprotonated intermediate an imine compound of the formula:
R N
A-III
to produce an aziridine substituted furanone compound of the formula:
Figure imgf000012_0001
Al-I
where
each of a and b is a chiral center;
R is alkyl, haloalkyl, aryl, aralkyl, alkenyl, aralkenyl, cycloalkyl, heteroalkyl, or
heteroaryl;
X is a leaving group; and
Y is an auxiliary group.
[0039] It should be appreciated that compound of Formula Al-II can also include one or more substituents (e.g., alkyl, halo, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl heterocycloalkyl, haloalkyl, etc.) on the a-position of the carbonyl group.
[0040] In some embodiments, Y is a chiral auxiliary group. One skilled in the art having read the present disclosure can envision and utilize a variety of chiral auxiliary groups. In one particular embodiment, said chiral auxiliary group is a moiety of the formula:
Figure imgf000012_0002
where
the squiggly line indicates the point of attachment of the chiral auxiliary group to the nitrogen atom;
* denotes a chiral center; and
Ra is alkyl, cycloalkyl, aralkyl, alkenyl, aralkenyl, heteroalkyl, or heteroaryl.
[0041] Typically, the imine compound A-III has enantiomeric excess of at least 90 %ee, typically at least 95 %ee, and often at least 99 %e.e. Accordingly, in some instances, the aziridine substituted furanone compound that is produced by the method of the invention is diastereomerically enriched. In some embodiments, the method of invention produces the aziridine substituted furanone compound of Formula Al-I in a diastereomeric excess of at least 90% de, typically at least 95% de, and often at least 98% de.
[0042] In some embodiments, the method of invention includes a step of removing the chiral auxiliary group. Removal of the chiral auxiliary group Y provides an aziridine substituted furanone compound in which only the chiral centers "a" and "b" are present.
[0043] Yet in other embodiments, the method provides an aziridine substituted compound whose enantiomerically enrichment is at least about 90%, typically at least about 95%), and often at least about 98%>.
[0044] A wide variety of methods are known to one skilled in the organic chemistry for removing the chiral auxiliary group. Such methods depend on the nature of the chiral auxiliary group that is used in the initial reaction. For example, for a chiral auxiliary group of formula A- IV, one of the method for removing the chiral auxiliary group is illustrated in the Examples section as well as on the commonly assigned U.S. Provisional Patent Application No.
62/027,209, filed on July 21, 2014, which is incorporated herein by reference in its entirety.
[0045] Method for producing Dihydrofuran Compounds : Another aspect of the invention provides a method for producing a dihydrofuran compound. In one particular embodiment of the invention, the reaction involves deprotonating an α,β-unsaturated compound of the formula:
B-2
with a base under condition sufficient to produce a deprotonated intermediate; and reacting said deprotonated intermediate an aldehyde compound of the formula:
Figure imgf000013_0001
B-III
a dihydrofuran compound of the formula:
Figure imgf000014_0001
B-I
where
W is an electron withdrawing group;
X is a leaving group; and
R is alkyl, haloalkyl, heteroalkyl, aryl, aralkyl, alkenyl, aralkenyl, cycloalkyl, heteroalkyl, or heteroaryl.
[0046] It should be appreciated that the compound B-2, can also include one or more substituents (e.g., alkyl, halo, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroaralkyl heterocycloalkyl, haloalkyl, etc.) on the α, β and/or γ-position of the electron withdrawing group, W.
[0047] The method of the invention provides a dihydrofuran compound in a yield of at least about 50%, typically at least about 60%, and often at least about 75%.
[0048] Additional objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples thereof, which are not intended to be limiting. In the Examples, procedures that are constructively reduced to practice are described in the present tense, and procedures that have been carried out in the laboratory are set forth in the past tense.
EXAMPLES
Figure imgf000014_0002
[0049] Example 1: General Procedure for the Synthesis of aziridine substituted fur anone compounds: To a flask equipped with magnetic stir bar and diisopropyl amine (2.0 eq. in THF, - 78 °C) was added «-butyl lithium (2.0 eq.) after which the solution was warmed to 0 °C and allowed to stir for 15 minutes. The resulting lithium diisopropyl amide (LDA) solution was then cooled to -78 °C and additional THF was added to reach an overall concentration of 0.1 M based on the sulfinimine. To the LDA solution, O. IM THF solution of 3-bromomethyl-2-buten-4-olide (1.2 eq.) was added, stirred for 30 minutes then solution of the respective sulfinimine (1.0 eq., 1M in THF) was then added using a syringe pump (0.5 mL/h) while the reaction temperature was maintained at -78 °C and allowed to stir for additional 3 hours after addition was complete. The reaction was then quenched with saturated ammonium chloride and allowed to warm to room temperature, extracted using ethyl acetate (3 times) and washed with brine. The combined organic extracts were dried using anhydrous sodium sulfate (Na2S04) and solvent evaporated. Crude material was purified by flash column chromatography (silica gel, 20-50% EtOAc in hexanes) to afford the respective compound, which are shown below:
R
) {
)
Figure imgf000015_0001
(3:1 cis/trans)
Figure imgf000015_0002
(3:1 cis/trans) 44% 53%
[0050] Example 2: Using the corresponding enantiomer of the imine compound, a similar yield of the an enantiomer of compounds produced in Example 1 were also obtained as illustrated below.
Figure imgf000016_0001
R -
(3:1 ds/trans)
[0051] Example 3: General Procedure for the Synthesis of dihydrofuran compounds: To a flask equipped with magnetic stir bar and diisopropyl amine (3.0 eq. in THF, -78 °C) was added «-butyl lithium (2.0 eq.) after which the solution was warmed to 0 °C and allowed to stir for 15 minutes. The resulting lithium diisopropyl amide (LDA) solution was then cooled to -78 °C and additional THF was added to reach an overall concentration of 0.1 M based on the sulfinimine. To the LDA solution, neat ethyl-4-bromocrotonate (1.2 eq.) was added, stirred for 30 minutes then solution of the aldehyde (1.0 eq., 1M in THF) was then added using a syringe pump (0.5 mL/h) while the reaction temperature was maintained at -78 °C and allowed to stir for additional 4 hours after addition was complete. The reaction was then quenched with saturated ammonium chloride and allowed to warm to room temperature, extracted using ethyl acetate (3 times) and washed with brine. The combined organic extracts were dried using anhydrous sodium sulfate (Na2S04) and solvent evaporated. Crude material was purified by flash column chromatography (silica gel, 10-15 % EtOAc in hexanes).
[0052] Some of the representative compounds produced using the method of the invention are shown below:
Br^^s^C°2Et
Figure imgf000017_0001
Figure imgf000017_0002
[0053] The foregoing discussion of the invention has been presented for purposes of illustration and description. The foregoing is not intended to limit the invention to the form or forms disclosed herein. Although the description of the invention has included description of one or more embodiments and certain variations and modifications, other variations and modifications are within the scope of the invention, e.g., as may be within the skill and knowledge of those in the art, after understanding the present disclosure. It is intended to obtain rights which include alternative embodiments to the extent permitted, including alternate, interchangeable and/or equivalent structures, functions, ranges or steps to those claimed, whether or not such alternate, interchangeable and/or equivalent structures, functions, ranges or steps are disclosed herein, and without intending to publicly dedicate any patentable subject matter. All references cited herein are incorporated by reference in their entirety.

Claims

What is Claimed is:
1. A method for producing an aziridine substituted furanone compound of the formula:
Figure imgf000018_0001
Al-I
said method comprising:
deprotonating an α,β-unsaturated compound of the formula:
Figure imgf000018_0002
Al-II
with a base under condition sufficient to produce a deprotonated intermediate; and reacting said deprotonated intermediate an imine compound of the formula:
Figure imgf000018_0003
A-III
under conditions sufficient to produce said aziridine substituted furanone compound of Formula Al-I,
wherein
each of a and b is a chiral center;
R is alkyl, haloalkyl, aryl, aralkyl, alkenyl, aralkenyl, cycloalkyl, heteroalkyl, or
heteroaryl;
X is a leaving group; and
Y is an auxiliary group.
2. The method of Claim 1, wherein Y is a chiral auxiliary group.
3. The method of Claim 2, wherein said chiral auxiliary group is a moiety of the formula:
Figure imgf000019_0001
wherein
* denotes a chiral center; and
Ra is alkyl, cycloalkyl, aralkyl, alkenyl, aralkenyl, heteroalkyl, or heteroaryl.
4. The method of Claim 3, wherein said imine compound of Formula A-III has enantiomeric excess of at least 99 % e.e.
5. The method of Claim 4, wherein said aziridine substituted furanone compound is diastereomerically enriched.
6. The method of Claim 5, wherein the diastereomeric excess of said aziridine substituted furanone compound is at least 95% d.e.
7. The method of Claim 4, wherein said imine compound is of the formula:
Figure imgf000019_0002
wherein
R is as defined in Claim 1; and
Ra is as defined in Claim 3.
8. The method of Claim 7, wherein Ra is tert-butyl.
9. The method of Claim 7, wherein said aziridine substituted furanone compound is of the formula:
Figure imgf000019_0003
enantiomer thereof, wherein
a, b and R are as defined in Claim 1; and
Ra are as defined in Claim 3.
10. A method for producing an aziridine compound of the formula:
Figure imgf000020_0001
A-I
said method comprising:
deprotonating an α,β-unsaturated compound of the formula:
R
A-II
with a base under condition sufficient to produce a deprotonated intermediate; and reacting said deprotonated intermediate an imine compound of the formula:
R N
A-III
under conditions sufficient to produce said aziridine compound of Formula A-I, wherein
each of a and b is a chiral center;
R is alkyl, haloalkyl, aryl, aralkyl, alkenyl, aralkenyl, cycloalkyl, heteroalkyl, or
heteroaryl;
R1 is hydrogen, alkyl, haloalkyl, aryl, aralkyl, alkenyl, aralkenyl, cycloalkyl, heteroalkyl, or heteroaryl; or R1 together with W form a heterocycloalkyl
X is a leaving group;
W is an electron withdrawing group; and
Y is an auxiliary group.
11. The method of Claim 10, wherein Y is a chiral auxiliary group.
12. The method of Claim 11, wherein said chiral auxiliary group is a moiety of the formula:
Figure imgf000021_0001
wherein
* denotes a chiral center; and
Ra is alkyl, cycloalkyl, aralkyl, alkenyl, aralkenyl, heteroalkyl, or heteroaryl.
13. The method of Claim 12, wherein said imine compound of Formula A-III has enantiomeric excess of at least 99 % e.e.
14. The method of Claim 13, wherein said aziridine compound is diastereomerically enriched.
15. The method of Claim 14, wherein the diastereomeric excess of said aziridine compound is at least 95% d.e.
16. The method of Claim 13, wherein said imine compound is of the formula:
Figure imgf000021_0002
wherein
R is as defined in Claim 9; and
Ra is as defined in Claim 12.
17. The method of Claim 16, wherein Ra is tert-butyl.
18. A method for producing a dihydrofuran compound of the formula:
Figure imgf000021_0003
B-I
said method comprising:
deprotonating an α,β-unsaturated compound of the formula: B-II
with a base under condition sufficient to produce a deprotonated intermediate; and reacting said deprotonated intermediate an aldehyde compound of the formula:
Figure imgf000022_0001
B-III
under conditions sufficient to produce said dihydrofuran compound of Formula B-I, wherein
W is an electron withdrawing group;
X is a leaving group; and
R is alkyl, haloalkyl, heteroalkyl, aryl, aralkyl, alkenyl, aralkenyl, cycloalkyl, heteroalkyl, or heteroaryl.
19. The method of Claim 18, W is an esters, sulfonyl, alkylsulfate, aldehydes, nitro, nitrile, phosphonate, amide, ketones or other electron withdrawing group containing a
heteroatom known to one skilled in the art.
20. The method of Claim 19, W is an ester.
21. The method of Claim 18, wherein X is halide.
22. The method of Claim 18, wherein R is alkyl or heteroalkyl.
PCT/US2016/041816 2015-07-10 2016-07-11 ORGANIC REACTION UTILIZING AN α,β-UNSATURATED COMPOUND WO2017011418A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562190924P 2015-07-10 2015-07-10
US201562190928P 2015-07-10 2015-07-10
US62/190,924 2015-07-10
US62/190,928 2015-07-10

Publications (1)

Publication Number Publication Date
WO2017011418A1 true WO2017011418A1 (en) 2017-01-19

Family

ID=57758063

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/041816 WO2017011418A1 (en) 2015-07-10 2016-07-11 ORGANIC REACTION UTILIZING AN α,β-UNSATURATED COMPOUND

Country Status (1)

Country Link
WO (1) WO2017011418A1 (en)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHOGII ET AL.: "Asymmetric [3+2] Annulation Approach to 3-Pyrrolines: Concise Total Syntheses of (-)-Supinidine, (-)-Isoretronecanol, and (+)-Elacomine", ANGWEDANTE CHEMIE INTERNATIONAL EDITION, vol. 54, 2015, pages 13706 - 13710, XP055345017, Retrieved from the Internet <URL:http://onlinelibrary. wiley .com/doi/10.1002/anie.201506559/abstract; jsessionid=5016B0BECE3573A8DAE62E68437C0E3E.f02t04> [retrieved on 20161021] *
JARVIS ET AL.: "Preparation and ring-opening reactions of N-diphenylphosphinyl vinyl aziridines", BEILSTEIN JOURNAL OF ORGANIC CHEMISTRY, vol. 9, 2 May 2013 (2013-05-02), pages 852 - 859, XP055345014, Retrieved from the Internet <URL:https://www.beilstein-journals.org/bjoc/content/pdf/1860-5397-9-98.pdf> [retrieved on 20161021] *
LIN ET AL.: "Stereocontrolled Construction of Tricyclic Furan and Pyrrolyl Derivatives via . Tungsten-Mediated [3+2] Cycloaddition and Intramolecular Diels-Alder Reaction", SYNTHESIS, 2002, pages 2457 - 2463, XP055345016 *
ZHENG ET AL.: "Telluronium Salts Mediated Aziridination of Chiral N-tert-Butylsulfinylimines: Highly Stereoselective Synthesis of Optically Active Vinylaziridines", ORGANIC LETTERS, vol. 7, no. 26, 23 November 2005 (2005-11-23), pages 5789 - 5792, Retrieved from the Internet <URL:http://pubs.acs.org/doi/abs/10.1021/ol051921n> [retrieved on 20161021] *

Similar Documents

Publication Publication Date Title
CN109311801B (en) Crystal forms and synthesis methods of (2R,6R) -hydroxynorketamine and (2S,6S) -hydroxynorketamine
KR101207529B1 (en) 4-substituted pyrrolidin-2-ones and their use
KR101395377B1 (en) Hiv protease inhibitors and pharmaceutical compositions comprising the same
Shevchuk et al. New asymmetric approach to β-trifluoromethyl isoserines
CN102858759B (en) For the preparation of the method for nebivolol
CN1964942A (en) Process for preparing 2-oxo-1-pyrrolidine derivatives by intramolecular allylation
EA023266B1 (en) Synthesis routes to 2(s),4(s),5(s),7(s)-2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoyl amides
CN108689903A (en) A kind of new preparation method of Bu Waxitan
US10450282B2 (en) Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols
CA2510280C (en) Process for the preparation of the r,r (or s,s) configured glycopyrronium stereoisomer
WO2017011418A1 (en) ORGANIC REACTION UTILIZING AN α,β-UNSATURATED COMPOUND
JP2006500407A (en) Methods for the synthesis of intermediates useful for the synthesis of tubulin inhibitors
KR19990067824A (en) Process for the preparation of 3-amino-pyrrolidine derivatives
Davies et al. Asymmetric syntheses of dihydroxyhomoprolines via doubly diastereoselective lithium amide conjugate addition reactions
JPH09500131A (en) Method for producing HIV protease inhibitor
JP2011057665A (en) Method for producing optically active 1-amino-2-vinylcyclopropanecarboxylic acid ester
JP2020511471A (en) Novel chiral dihydrobenzazaphosphole ligands and their synthesis
KR100915551B1 (en) Process for the efficient preparation of 3-hydroxy pyrrolidine and derivatives thereof
CN114269338A (en) Process and intermediates for producing diazaspiro lactam compounds
DE69221733T3 (en) BETA PHENYLISOSERINE (2R, 3S), THEIR SALTS, PRODUCTION AND USE
Fukuda et al. Synthesis of both enantiomers of protoberberines via laterally lithiated (S)-4-isopropyl-2-(o-tolyl)-oxazolines
WO2016014426A1 (en) Organic reactions
DE4224342A1 (en) Process for the preparation of enantiomerically pure ß-substituted Ï-aminobutyric acid derivatives, new enantiomerically pure intermediates of this process and their use
DE60008270T2 (en) METHOD FOR PRODUCING OXAZOLINES FROM TETRAHYDROFURANES
Badorrey et al. Stereocontrolled synthesis of all four stereoisomers of fully protected 2-amino-3-hydroxypentanoic acid from imines derived from d-glyceraldehyde

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16825012

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16825012

Country of ref document: EP

Kind code of ref document: A1